In addition, a combination of capmatinib (INC280) and gefitinib was tested in a phase 2 study (NCT01610336) in EGFR-mutant NSCLC patients after acquired resistance to gefitinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.